Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
April 17th 2025The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
March 18th 2025The new device from Lumenis aids in ocular surface disease treatment by combining radio frequency and dynamic muscle stimulation to improve lower lid laxity, enhance blink dynamics, and offer a non-invasive solution for dry eye management.
FDA approves ranibizumab for the treatment of diabetic macular edema via continuous delivery implant
February 4th 2025Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.